96 results about "Recombinant GH" patented technology

The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.

Modified growth hormone polypeptide and uses thereof are provided.

The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose- related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

The present invention relates to growth hormone-releasing hormone (GHRH) analogues. More particularly, the invention relates to synthetic GHRH analogues of 29 amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH2. The present invention also relates to a pharmaceutical composition comprising any one of said GHRH analogues and to the use of these analogues for specific stimulation of in vivo GH release as well as preparation of a drug in the treatment of GH deficiency-related conditions. The present invention also provides for a method for initiating GHRH-induced biological actions in a mammal.

The present invention relates, in part, to methods for increasing the size of a subject by administering a delivery construct comprising growth hormone to a subject. In one aspect, the method for increasing the size of a subject by at least about 12% comprises contacting an apical surface of a polarized epithelial cell of the subject with an amount of a delivery construct comprising growth hormone that is effective to increase the size of the subject by at least about 12%.

Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.

There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells. The higher inhibitory potencies of the new analogs, as compared to previously described ones, results from replacement of various amino acids.

The invention discloses recombinant oral protein TAT-GH of tilapia, a preparation method for the recombinant oral protein TAT-GH and application of the recombinant oral protein TAT-GH. The method comprises the following steps of: extracting total messenger ribonucleic acid (mRNA) from a pituitary gland of male tilapia, performing reverse transcription-polymerase chain reaction (RT-PCR) to obtain complementary deoxyribonucleic acid (cDNA), performing PCR amplification to obtain a growth hormone (GH) gene of the tilapia, and amplifying a TAT-GH gene by a PCR overlap extension method; constructing a recombinant plasmid pET-32a(+)-TAT-GH; and transforming Escherichia coli BL21 (DE3) by using the recombinant plasmid pET-32a(+)-TAT-GH, efficiently expressing fusion protein TAT-GH in the form of an inclusion body under the induction of isopropyl thiogalactoside (IPTG), and purifying and renaturing to obtain active protein. The protein can effectively promote the growth and development of fries of the tilapia after being fed to the fries of the tilapia.

Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.

The present invention comprises growth hormone releasing peptides / peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.

The fusion protein may be expressed from a polynucleotide having a promoter element and / or a transcription termination sequence, in each case operatively associated with a polynucleotide encoding the fusion protein. The yeast may be S. cerevisiae, S. pombe, Pichia (Hansenula) sp. or Kluyveromyces sp.

The present invention belongs to the field of animal gene engineering, and is especially the cloning and polymorphism application of goat's growth hormone (GH) gene. The present invention features that two DNA sequences of goat's GH gene as shown is obtained through cloning and two base mutations affecting goat's growth characters are detected. The present invention discloses two goat's GH gene sequences and two base mutational sites affecting goat's growth characters. The present invention also discloses the preparation process and application of the said genes, and provides new molecular markers for the auxiliary selection of goat's growth characters.

Growth hormone-releasing hormone analogs having the amino acid sequence of the formula: Dat-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr10-R11-R12-VAL-Leu-Ala-Gln-Leu-Ser-Ala-R20-R21-Leu-Leu-Gln-Asp-Ile-Nle-Asp-R29-NH2 (I), wherein R11 is hArg, Gab or Gap; R12 is hArg, Orn, Gab or Gap; R20 is hArg, hArg, Gab or Gap; R21 is hArg, Orn, Gab or Gap; R29 is D-Arg, hArg, Gab or Gap; and their pharmaceutically acceptable salts. Said peptides are potent and selective stimulators of GH release and they are highly resistant to enzymatic degradation. Said peptides are prepared using the solid phase synthesis method, by introducing suitable derivatives of lysine, 2,4-diaminobutyric acid or 2,3-diaminopropionic acid at appropriate positions in the peptide chain attached to a polymeric support, deprotecting side-chain amino groups and reacting free amino groups with a guanidinating agent, removing all remaining t-butyloxycarbonyl protective groups, and cleaving the synthesized peptide from the support, followed by purification and optionally, converting the peptide into a pharmaceutically acceptable salt.

The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.

The invention relates to a gene recombinant human growth hormone modification substance for treating microsoma caused by children's endogenous recombinant human growth hormone deficiency or insufficiency and for surgeries for injuries and serious burns and subsequent treatment, particularly a preparation method of a polyethyleneglycol (PEG) modification substance of the growth hormone. The invention aims to provide a preparation method of a recombinant human growth hormone, which is higher in expression level and convenient for operation, can enhance the purity and activity of the effective drug and can enhance the purity and activity of the product on the premise of not increasing the cost, thereby enhancing the activity of the drug. The invention also aims to provide a preparation method of the recombinant human growth hormone PEGylation modification substance. According to the method, the PEGylation is utilized to modify the drug, so that the PEG and human growth hormone are connected through covalence, thereby prolonging the half life of the drug and lowering the toxic or side effect of the drug protein.

The invention discloses a method for rapidly detecting the single nucleotide polymorphism (SNP) of goat homeobox 6 (six6) gene, using the whole genome DNA of the goat to be tested containing the Six6 gene as a template, and using a primer pair P as Primers, PCR amplified goat Six6 gene; after the PCR product was digested with restriction endonuclease PstI, agarose gel electrophoresis was carried out; the genotype at position 232 of the goat Six6 gene was identified according to the electrophoresis results (with sequence Accession No.NM_001104993. 1 for reference); in animal production practice, since the Six6 gene single nucleotide variation or SNP has important effects on the formation of embryos, regulation of growth hormone and promotion of pituitary hormone secretion, the different genotypes of the site are related to growth and development Association analysis of trait data. The results showed that the tube circumference of CT genotype individuals was significantly larger than that of CC genotype individuals (P=0.047), indicating that CT genotype can be used as a molecular genetic marker to increase tube circumference in goats. Therefore, the detection method for rapid detection of Six6 gene SNP provided by the present invention is conducive to the rapid establishment of goat populations with excellent genetic resources in the marker-assisted selection (MAS) breeding of Chinese goat growth traits.

The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

A series of novel synthetic analogs of hGH-RH(1-29)NH2 are provided herein. These analogs inhibit the activity of endogenous hGH-RH, thus hindering the release of growth hormone. Compared with the previously described analogs, the stronger inhibitory ability of the novel analogs is due to multiple amino acid substitutions.

There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells. The higher inhibitory potencies of the new analogs, as compared to previously described ones, results from replacement of various amino acids.

The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems / oligomers of said modified growth hormone binding domains.

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.

The invention discloses a method for industrially producing grouper growth hormone recombination gene protein. The method comprises the steps of constructing a cloning vector pGEMT-gGH, constructing a yeast expression vector pPICZaA-gGH, acquiring grouper growth hormone recombination gene-containing pichia pastoris, conducting fermentation in self-control tank, conducting aftertreatment and the like. With the method for industrially producing grouper growth hormone recombination gene protein, the industrial production of the grouper growth hormone recombination gene protein can be realized, the production cost can be greatly lowered, and high-output and stable grouper growth hormone recombination gene protein products can be obtained, thereby providing practical products for truly realizing large-scale application in grouper cultivation production, and prompting the health growth of the groupers.

The invention discloses a [beta]-actin promoter, a growth hormone gene and a 3<,>-untranslated region (3<,> UTR) of pseudobagrus fulvidraco richardson, and a pseudobagrus-fulvidraco-richardson-origin transgenic vector constructed with the [beta]-actin promoter, the growth hormone gene, and the 3<,> UTR as elements. According to the invention, sequences of the pseudobagrus fulvidraco richardson [beta]-actin promoter, sequences of exon 1, sequences of partial exon 2, amino acid data-encoding sequences of the growth hormone gene, and sequences of the 3<,> UTR are acquired. The pseudobagrus-fulvidraco-richardson-origin transgenic vector is constructed with the obtained [beta]-actin promoter, the obtained growth hormone gene, and the obtained 3<,> UTR as elements. According to the invention, the transgenic vector is constructed through driving the growth hormone gene expression of pseudobagrus fulvidraco richardson by the [beta]-actin promoter of its own. With the technical scheme of the present invention, biosafety problems of faced by transgenic fish can be effectively avoided. Therefore, the invention has great practical significance and application prospects in the genetic breeding and artificial fertilizing of pseudobagrus fulvidraco richardson.

The invention belongs to the technical field of functional study of polypeptide and discloses a polypeptide PP1 capable of promoting expression of growth hormone of tilapia mossambica and application thereof. The amino acid sequence of the polypeptide PP1 is YPVPLENPGPADPAEEL. By intraperitoneal injection of tilapia mossambica by a solution of the polypeptide PP1, results display that the PP1 can obviously promote the expression level of growth hormone in hypophysis cerebri of tilapia mossambica and has physiological activity. The polypeptide PP1 disclosed by the invention can be used for preparing an oral preparation for improving GHmRNA expression of hypophysis cerebri or fish offspring seed growth promoters or additives.

The invention discloses a quantitative detection kit for growth hormone. The quantitative detection kit comprises an experimental buffer solution, concentrated washing liquor, an enhancement solution, a coated plate, a standard product, a quality control product and a marker, wherein the enhancement solution is prepared from 1 to 5 mg / L of beta-naphthoyltrifluoroacetone, 15 to 30 mg / L of tri-n-octylphosphine oxide and a third buffer solution; the coated plate is prepared from coating liquid, confining liquid and a reaction plate; the coating liquid is prepared from 1 to 10 ppm of Proclin300, a fourth buffer solution and 1 to 10 [mu]g / ml of a growth hormone monoclonal antibody; the confining liquid is prepared from 1.0 to 10.0 g / L of trehalose, bovine serum albumin with the mass volume ratio of 0.4 to 0.6 percent and the fourth buffer solution; the standard quality and the quality control product are filter paper dried blood pieces; the filter paper dried blood pieces comprise mixtures with 8 concentrations; the mixtures comprise red blood cells, de-hormone negative serum mixed matrixes and the growth hormone; and the marker is prepared from the growth hormone monoclonal antibody and a lanthanide ion chelate according to (1: 1) to (1: 6) m / m. The invention further discloses a preparation method of the kit. The kit disclosed by the invention can ensure that a detection result is highly consistent with a detection result of a serum sample.

The present invention is directed towards a diagnostic test, treatment, and monitoring of treatment for growth hormone abnormalities including Growth Hormone Deficiency (“GHD”) as well as a kit comprising the necessary components of the present invention. G-protein expression and levels of mRNA are evaluated to determine if a patient has GHD or if treatment for GHD is effective. A G-protein agonist or antagonist is used to treat GHD by bringing G-protein expression and levels of mRNA into the normal range.

The present invention relates to a novel process for the purification of growth hormone polypeptides, e.g. recombinant human Growth Hormone. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of Growth Hormone from closely related proteins.

The invention discloses a recombinant pig growth hormone and a preparation method and application thereof. The preparation method comprises the following steps of: inserting a polynucleotide sequencecontaining a plurality of pig growth hormone full-length sequences into a pichia pastoris expression vector to obtain a recombinant plasmid; introducing the recombinant plasmid into a pichia pastoriscompetent cell to construct a recombinant engineering bacterium; and performing fermentation expression and protein purification on the recombinant engineering bacterium to obtain a target protein, namely the recombinant pig growth hormone. The recombinant pig growth hormone can be applied as a pig feed additive. The recombinant pig growth hormone has the advantages that the protein molecular weight is increased by adopting a multi-linkage mode, so that the problem that the hormone is digested in the stomach and loses functions is solved; meanwhile, a plurality of repeated fragments exist, sothat the problem of short half-life period can be well solved; and in addition, the recombinant pig growth hormone is produced by adopting a recombination mode, is simpler and lower in cost compared with an extraction method, and can be widely applied as the feed additive.